EQS-News: 28th Annual BIO-Europe® to bring together over 4,300 life science leaders 12.10.2022, 10:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: EBD Group / Key word(s): Conference
28th Annual BIO-Europe® to bring together over 4,300 life science leaders

12.10.2022 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

28th Annual BIO-Europe® to bring together over 4,300 life science leaders

Munich, Germany – October 12, 2022: The 28th annual BIO-Europe® global life sciences partnering event will take place October 24–26, 2022 in Leipzig, Germany. With less than two weeks away, over 33,000 meeting requests have already been submitted. A diverse audience from over 62 countries is expected to come together for the biopharma reunion of the year.

The live opening keynote plenary discussion “Opportunities created by a bear market - There is a silver lining” on Monday, October 24, will feature speakers Werner Lanthaler, CEO, Evotec, Sander Slootweg,  Managing Partner, Forbion Capital Partners, Detlev Mennerich, SVP, heading Global BD&L, Boehringer Ingelheim, Christian Rommel, Head of Research and Development and Member of the Executive Committee, Bayer Pharmaceuticals, Philippe Lopes-Fernandes, Executive Vice President and Chief Business Officer, IPSEN.

Tuesday will feature the popular session, “A day in the life of a dealmaker” with Matthias Müllenbeck, SVP, Head Global Business Development & Alliance Management, Merck KGaA, Darmstadt, Germany, Jenny Laird, VP, Search & Evaluation Neuroscience, Lilly, Nouhad Husseini, Head of BD, Regeneron.

We are also excited to bring back the Startup Spotlight, a lively competition offering selected startup companies to make a 4-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner.

Additionally, high-level executives from pharma, biotech, and the investment sector are confirmed to participate in panels and fireside chats covering a wide range of topics – dealmaking in various therapeutic areas, finance and investment dedicated track, regional case studies and close up collaborations on the open stage within the exhibit hall.

This year’s conference takes place in Leipzig, Germany, and is supported by regional host biosaxony. The event is expected to bring together over 4,300 executives from life sciences companies spanning an estimated 60+ countries to engage in one-to-one partnering.

Early bird rates are still available until October 14: registration information for BIO-Europe is available online.

For more information and live updates, please visit the conference website at: informaconnect.com/bioeurope and follow BIO-Europe 2022 on Twitter @EBDGroup (hashtag: #BIOEurope) and on LinkedIn.

BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).

About EBD Group

EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, ChinaBio® Partnering Forum, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. EBD Group is an Informa company. For more information, please visit www.ebdgroup.com.

Media Contacts:
MC Services AG
+49 89 2102280
contact@mc-services.eu

EBD Group
Karina Marocco
kmarocco@ebdgroup.com



12.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1461237  12.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1461237&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 20:31 Uhr • Artikel • dpa-AFX

Gestern 20:07 Uhr • Artikel • dpa-AFX

Gestern 19:58 Uhr • Artikel • dpa-AFX

Gestern 19:53 Uhr • Artikel • dpa

Gestern 19:47 Uhr • Artikel • dpa-AFX

Gestern 19:38 Uhr • Artikel • dpa-AFX

Gestern 19:30 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer